- Home
- FOLD vs VCYT Comparison
FOLD vs VCYT Comparison
Compare FOLD & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- VCYT
- Stock Information
- Founded
- FOLD 2002
- VCYT 2006
- Country
- FOLD United States
- VCYT United States
- Employees
- FOLD N/A
- VCYT N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- VCYT Medical Specialities
- Sector
- FOLD Health Care
- VCYT Health Care
- Exchange
- FOLD Nasdaq
- VCYT Nasdaq
- Market Cap
- FOLD 2.5B
- VCYT 2.6B
- IPO Year
- FOLD 2007
- VCYT 2013
- Fundamental
- Price
- FOLD $8.15
- VCYT $34.84
- Analyst Decision
- FOLD Strong Buy
- VCYT Buy
- Analyst Count
- FOLD 9
- VCYT 9
- Target Price
- FOLD $26.44
- VCYT $39.89
- AVG Volume (30 Days)
- FOLD 5.8M
- VCYT 895.7K
- Earning Date
- FOLD 11-05-2025
- VCYT 11-05-2025
- Dividend Yield
- FOLD N/A
- VCYT N/A
- EPS Growth
- FOLD N/A
- VCYT N/A
- EPS
- FOLD N/A
- VCYT 0.34
- Revenue
- FOLD $571,160,000.00
- VCYT $479,129,000.00
- Revenue This Year
- FOLD $20.98
- VCYT $14.48
- Revenue Next Year
- FOLD $20.74
- VCYT $9.79
- P/E Ratio
- FOLD N/A
- VCYT $102.86
- Revenue Growth
- FOLD 25.35
- VCYT 19.91
- 52 Week Low
- FOLD $5.51
- VCYT $22.61
- 52 Week High
- FOLD $12.65
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- FOLD 56.40
- VCYT 59.94
- Support Level
- FOLD $7.69
- VCYT $31.81
- Resistance Level
- FOLD $8.59
- VCYT $36.85
- Average True Range (ATR)
- FOLD 0.37
- VCYT 1.40
- MACD
- FOLD -0.05
- VCYT 0.06
- Stochastic Oscillator
- FOLD 54.44
- VCYT 60.91
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.